Clinical Trials
This page highlights promising and innovative clinical trials for glioblastoma. We focus on emerging treatments that may offer new options and deserve closer attention from patients, caregivers, and clinicians.
Overview Clinical Trials
Phase II (NCT07708961)
Phase I (NCT07648823)
Phase I (NCT07579208)
Phase I (NCT07552233)
Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 in Recurrent Glioblastoma
NK Cell Therapy for Malignant Solid Brain Tumors
Overview Clinical Trials
Phase III (NCT07195591)
Phase II (NCT06805305)
Phase III (NCT06419946)
Phase III (NCT06097975)
Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI)